miRview® meso utilizes proprietary technology developed by Rosetta Genomics. This technology includes protocols for the extraction of microRNA from formalin-fixed paraffin-embedded (FFPE) tissue samples and quantification of the relative amounts of specific microRNAs using quantitative real-time polymerase chain reaction (qRT-PCR) technology to indicate the levels of mesothelioma- and non-mesothelioma―specific microRNA markers.

miRview® meso is the product of two years of research with hundreds of tumor samples. In the first phase of development, more than 100 tumor samples (including mesothelioma and non-mesothelioma cancer samples) were studied by high-throughput molecular profiling¹. Molecular profiling using microRNA microarrays was used to identify the molecular markers for mesothelioma or other cancers¹. In the second phase, the microRNA markers were validated and a diagnostic assay defined using sensitive and specific proprietary qRT-PCR technology¹.
The performance of the miRview® meso assay was determined in an independent, blinded test. The sensitivity and specificity of this assay have been shown to be 100% and 94%, respectively².

While many of the cancer tests currently available are largely qualitative and subjective, the measurement of microRNA expression levels in tissue samples offers a quantitative, objective diagnosis. Proprietary technologies enable microRNA profiling with high sensitivity and specificity (these values have been shown to be 100% and 94%, respectively)². In addition, microRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.

Download Product Profile

1. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.
2. Data on file, Rosetta Genomics.